Evidence map›Paper›PMID 31218232›Full record

ArticleJournal of diabetes research2019

Expression Profiling and Clinical Significance of Plasma MicroRNAs in Diabetic Nephropathy.

Jianqin Wang, Gouqin Wang, Yaojun Liang, Xiaochun Zhou

Abstract read
In one paragraph

Article in Journal of diabetes research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. The role of miRNAs in Behçet's disease.Frontiers in immunology · 2023
    Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jianqin WangDepartment of Nephropathy, Lanzhou University Second Hospital, No. 82 Cuiyingmen Lanzhou, Gansu province, China.ORCID 0000-0003-4020-2494
Gouqin WangDepartment of Nephropathy, Lanzhou University Second Hospital, No. 82 Cuiyingmen Lanzhou, Gansu province, China.
Yaojun LiangDepartment of Nephropathy, Lanzhou University Second Hospital, No. 82 Cuiyingmen Lanzhou, Gansu province, China.
Xiaochun ZhouDepartment of Nephropathy, Lanzhou University Second Hospital, No. 82 Cuiyingmen Lanzhou, Gansu province, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsMicroRNAs (miRNAs) stably and abundantly exist in body fluids and have been considered as novel and noninvasive biomarkers for several diseases. The present study is aimed at investigating the expression profiling and clinical significance of plasma miRNAs in the pathogenesis and progression of diabetic nephropathy (DN).

methodsPlasma samples were obtained from 66 DN patients (36 had microalbuminuria and 30 had macroalbuminuria), 36 diabetic patients with normoalbuminuria, and 40 healthy controls. The plasma miRNA profiles were obtained by miRNA low-density array chip and validated by quantitative real-time polymerase chain reaction. The correlations between the differential expression of plasma miRNAs and clinicopathological parameters were explored.

resultsmiR-150-5p, miR-155-5p, miR-30e, miR-320e, and miR-3196 were found to be differentially expressed in plasma samples among these three groups: diabetic patients with microalbuminuria, diabetic patients with normoalbuminuria, and healthy controls (

conclusionmiR-150-5p, miR-155-5p, miR-30e, miR-320e, and miR-3196 are potentially new diagnostic biomarkers for early DN. miR-150-5p and miR-155-5p may be involved in the pathogenesis and progression of DN. Further research is required to verify these findings and clarify the specific molecular mechanisms.

Indexed as

Gene Expression ProfilingAlbuminuriaBiomarkersBody FluidsCase-Control StudiesDiabetes Mellitus, Type 2Diabetic NephropathiesDisease ProgressionFemaleGenotypeGlomerular Filtration RateHumansMaleMicroRNAsMiddle AgedOligonucleotide Array Sequence AnalysisBiomarkersMicroRNAsMIR150, humanMIRN155 microRNA, humanMIRN30b microRNA, humanMIRN3196 microRNA, humanMIRN320 microRNA, human

Identifiers

PMID31218232
PMCPMC6536987

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.